Abbreviations used in this paper: BDM, 2,3-butanedione monoxime; PLV, porcine left ventricular muscle; SL, sarcomere length; Tn, troponin.

INTRODUCTION
============

Cardiac pump function is enhanced as ventricular filling is increased (i.e., the Frank-Starling law of the heart) ([@bib21]). The "Law of the Heart" is a manifestation of the sarcomere length (SL) dependence of myocardial activation, in which active force is a function of the resting SL ([@bib15]). The molecular mechanism of length-dependent activation is still not fully understood.

In striated muscle, the formation of strongly bound cross-bridges, i.e., attachment of myosin to actin, is a stochastic process ([@bib20]). It has therefore been proposed that the attachment probability increases as interfilament lattice spacing is reduced, resulting in an increase in Ca^2+^ sensitivity of force ([@bib15], and references therein). Recent studies using synchrotron x-ray diffraction have revealed that titin (originally known as connectin)-based passive force acts as an interfilament lattice spacing modulator within the physiological SL range in cardiac muscle ([@bib7]; [@bib14]). It has also been pointed out that titin-based passive force may strain the thick filament, allowing the shift of myosin heads from the thick filament backbone to the thin filament ([@bib13]).

It has however been reported that changes in the lattice spacing are not the only factor modulating length-dependent activation ([@bib22],[@bib23]; [@bib24]). Indeed, we previously varied the thin filament activation level, by changing the concentration of MgADP ([@bib11]) or inorganic phosphate ([@bib12]), and demonstrated that the length dependence is a function of the fraction of recruitable (i.e., resting) cross-bridges that can potentially produce additional active force upon attachment to actin ([@bib15]).

It is widely known that length-dependent activation is more pronounced in cardiac muscle than in skeletal muscle, within the physiological SL range (e.g., [@bib1]; [@bib2]; [@bib4]; [@bib18]). This difference likely results in part from the differential expression of titin in cardiac vs. skeletal muscle (e.g., [@bib17]); a higher passive force due to the shorter extensible I-band region of cardiac titin(s) may more effectively modulate the lattice spacing and/or the thick filament structure. It is also possible that the differential expression of troponin (Tn) in cardiac vs. skeletal muscle underlies the differing magnitude of length-dependent activation. Indeed, it was proposed that cardiac troponin C (TnC) may act as a unique "length sensor" that somehow senses changes in SL ([@bib4]; [@bib18]). However, this proposal was later challenged by the Moss group with a series of careful experiments ([@bib29]; [@bib26]) and, currently, is in dispute (see [@bib15]). Alternatively, it has been reported that troponin I (TnI) may modulate length-dependent activation by adjusting the on--off equilibrium of the thin filament state ([@bib3]; [@bib24]), consistent with our view that length-dependent activation depends on the fraction of recruitable cross-bridges.

The present study was accordingly undertaken to integrate the molecular mechanisms of length-dependent activation, focusing on how this phenomenon is regulated via on--off switching of the thin filament state in association with titin-based regulation.

MATERIALS AND METHODS
=====================

All experiments performed in the present study conform to the Guide for the Care and Use of Laboratory Animals (1996, National Academy of Sciences, Washington D.C.).

Preparation of Skinned Muscle and Measurement of Isometric Force
----------------------------------------------------------------

Active and passive forces were measured with skinned porcine left ventricular muscle (PLV), based on our previously published procedure ([@bib11], [@bib12],[@bib13], [@bib14]). Porcine hearts (animals, ∼1.0 yr) were obtained from a local slaughterhouse. Muscle strips (1−2 mm in diameter and ∼10 mm in length) were dissected from the papillary muscle of the left ventricle in Ca^2+^-free Tyrode\'s solution (135 mM Na^+^, 5 mM K^+^, 1 mM Mg^2+^, 98 mM Cl^−^, 20 mM HCO~3~ ^−^, 1 mM HPO~4~ ^2−^, 1 mM SO~4~ ^2−^, 20 mM acetate, 10 mM glucose, 5 IU/liter insulin, pH 7.35, when equilibrated with 5% CO~2~--95% O~2~ at 30°C) containing 30 mM 2,3-butanedione monoxime (BDM). Psoas muscles were obtained from white rabbits (2--3 kg).

Both cardiac and skeletal muscles were skinned in relaxing solution (5 mM MgATP, 40 mM *N,N*-bis(2-hydroxy-ethyl)-2-aminoethanesulfonic acid \[BES\], 1 mM Mg^2+^, 10 mM EGTA, 1 mM dithiothreitol \[DTT\], 15 mM phosphocreatine, 15 U/ml creatine phosphokinase, 180 mM ionic strength \[adjusted by K-propionate\], pH 7.0) containing 1% (wt/vol) Triton X-100 and 10 mM BDM overnight at ∼3°C ([@bib14]). Muscles were stored for up to 3 wk at −20°C in relaxing solution containing 50% (vol/vol) glycerol ([@bib14]). Passive and active forces did not change during this period (statistical tests failed to reveal a correlation between passive or active force and storage duration \[not depicted\]). All solutions contained protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride \[PMSF\], 0.04 mM leupeptin, 0.01 mM E64).

Small thin preparations (∼100 μm in diameter and ∼2 mm in length) were carefully dissected from the above strips for isometric force measurement ([@bib14]). Single fibers were used for experiments with rabbit psoas muscle. SL was measured by laser diffraction during relaxation, and active and passive forces were measured at 15°C according to our previously described procedure (pCa was obtained by adjusting the ratio of Ca/EGTA) ([@bib11], [@bib12],[@bib13]).

The muscle preparation was first immersed in high-EGTA (10 mM) relaxing solution, and SL was set at 1.9 μm. Just before contraction, it was immersed in low-EGTA (0.5 mM) relaxing solution, in order to avoid slowing of contraction ([@bib13]). The preparation was first activated at pCa 4.5 to obtain maximal Ca^2+^-activated force, followed by relaxation. The preparation was then activated at various pCa\'s (from high to low pCa, and lastly at pCa 4.5) to construct the force--pCa curve. Next, SL was increased to 2.3 μm, and 20 min after the SL elongation, the force--pCa curve was obtained. Active force was normalized to the maximal force at pCa 4.5 obtained at the end of experiment. The curves were fitted to the Hill equation, and the difference between the values of the midpoint (pCa~50~) of the force--pCa curve measured at SL 1.9 and 2.3 μm was used as an index of the SL dependence of Ca^2+^ sensitivity of force (i.e., ΔpCa~50~; see [@bib11], [@bib12],[@bib13]). We also obtained the Hill coefficient (n~H~). Passive force was measured just before activation at each pCa ([@bib14]).

In another series of experiments, the cardiac muscle preparation was activated ∼10 s after increasing SL to 2.3 μm, at a rate of 0.1 muscle length/s, before passive force reached the steady-state level (i.e., during stress relaxation; see [@bib14]), and hence at high passive force. In this protocol, a single activation--relaxation cycle was performed after which the muscle was released back to SL 1.9 μm, and 20 min later the same protocol was repeated but at a different pCa (from high to low, and finally at pCa 4.5).

To obtain titin-based passive force, the thick and thin filaments were extracted by immersing the muscle preparation in relaxing solution containing 0.6 M KCl and then in relaxing solution containing 1.0 M KI (45 min incubation for each; see [@bib14]). We assumed that titin-based passive force was equal to total passive force minus the remaining passive force after the KCl/KI treatment ([@bib14]).

Measurement of Force Redevelopment
----------------------------------

The rate of force redevelopment (*k* ~tr~) was measured based on previous studies ([@bib6]; [@bib27]), with modifications. A skinned cardiac muscle preparation, obtained as described above, was mounted horizontally in a chamber (model 802B, Aurora Scientific) between a force transducer (model 403A, Aurora Scientific) and a length controller (model 322C, Aurora Scientific). SL was measured during relaxation with a spatial autocorrelation function (model 901A HVSL, Aurora Scientific) through an inverted microscope (model Diaphot 300, Nikon) and a CCD camera (model IPX-VGA210-L, IMPERX), and adjusted to 1.9 μm. The length and force signals were digitized, controlled, and recorded by a 16-bit A/D and 16-bit D/A converter (model 600A, Aurora Scientific). In brief, the preparation was bathed in an activating solution and steady isometric force was allowed to develop. Subsequently, the muscle was rapidly slackened by 20% of its original length in 1 ms, followed by unloaded shortening for 20 ms after which it was stretched back to its original length in 1 ms. Force redevelopment following the slack-restretch maneuver and force recovery to the original steady-state value reflect the rate of cross-bridge cycling ([@bib6]; [@bib27]). A *k* ~tr~--pCa curve was obtained by first maximally activating the muscle at pCa 4.5, and then in a series of submaximally activating solutions at pCa 6.0, 5.75, 5.5, and 5.0 (in this order; pCa 6.0 was only used for skeletal Tn (sTn)--reconstituted muscles due to increased Ca^2+^ sensitivity of force), and lastly at pCa 4.5. *k* ~tr~ was obtained by fitting the force redevelopment process with a single exponential function: F(*t*) = F~ss~ × (1 − exp(−*k* ~tr~ *t*)) + F~res~, where F(*t*) is the force at any time *t* after restretch, F~ss~ is the steady-state force, and F~res~ is the residual force obtained immediately after the slack--restretch maneuver (regression coefficient R \> 0.7 for all data). Isometric force was measured just before the slack--restretch maneuver, and *k* ~tr~ was normalized at pCa 4.5 obtained at the end of experiment. Measurements were performed at 15°C.

Tn Exchange
-----------

The Tn exchange was performed based on our previously published procedure ([@bib32]), with modifications. The sTn complex was purified from rabbit fast skeletal muscle and stored at −80°C. In brief, after measuring active force (and *k* ~tr~) at pCa 4.5 at SL 1.9 μm, the cardiac muscle preparation was bathed in rigor solution (10 mM BES, 150 mM K-propionate, 2.5 mM EGTA, 5 mM MgCl~2~, pH 7.0) containing 2 mg/ml sTn and 80 mM BDM for 1 h at 25°C. The presence of BDM was found to be essential to avoid contraction upon Tn exchange and the ensuing damage to the sarcomere structure, allowing us to obtain two force--pCa curves at short and long SLs, with little or no rundown in active or passive force. Then, the preparation was washed with normal relaxing solution at 15°C for 10 min with gentle agitation to remove excess sTn, resulting in only a small (∼10%) increase in the band intensity of each Tn subunit upon sTn reconstitution.

Similarly, reconstitution was performed on single fibers of rabbit psoas muscle under the same condition for 1 h in the presence of the Tn complex purified from porcine left ventricular muscle (cTn; 6 mg/ml). cTn was stored at −80°C.

We also conducted a set of experiments where cardiac or skeletal muscle was treated with the Tn complex identical to the endogenous one. In these experiments, cardiac muscle was treated with 2 mg/ml cTn for 1 h, and skeletal muscle with 2 mg/ml sTn for 1 h (for both force measurements and gel electrophoreses).

Gel Electrophoresis
-------------------

SDS-PAGE was conducted based on the previous study ([@bib14]; [@bib38]). Muscle preparations were solubilized and electrophoresed on Laemmli gels (acrylamide, 3.5% in stack and 15% resolving gel; pH 9.3). Cardiac (N2B and N2BA isoforms) and skeletal titins were checked by using 2--7% acrylamide gradient gels. Gels were scanned and digitized (ES-2200, EPSON), and densitometry was performed using One-D-Scan (v. 2.03, Scanalytics Corporation). Tn isoforms were identified by commigration with known standards. We quantified the reconstitution ratio by comparing the ratio of troponin T (TnT) or TnI to actin with that obtained for the original muscle (i.e., either rabbit psoas or porcine left ventricular muscle).

Statistics
----------

Significant differences were assigned using the appropriate paired or unpaired Student\'s *t* test. Regression analysis was performed using the least-square method ([@bib13]). Data are expressed as mean ± SEM, with *n* representing the number of muscles. Statistical significance was assumed to be P \< 0.05. NS indicates P \> 0.05.

RESULTS
=======

Effect of sTn Reconstitution on Length-dependent Activation in Cardiac Muscle
-----------------------------------------------------------------------------

A representative 15% gel ([Fig. 1 A](#fig1){ref-type="fig"}, left) demonstrates that endogenous Tn subunits were effectively replaced by their rabbit fast skeletal counterparts in PLV. Subsequent treatment with cTn incorporated cardiac Tn subunits into the sTn-treated muscle by ∼40% (see legend of [Fig. 1 A](#fig1){ref-type="fig"} for quantitative analysis). Both N2BA and N2B titins were not degraded during Tn exchange ([Fig. 1 A](#fig1){ref-type="fig"}, right; see passive force in B and C).

![sTn reconstitution and its impact on length-dependent activation in PLV. (A, left) 15% gel. Cont., control PLV; sTn, sTn-reconstituted PLV; sTn-cTn, sTn-reconstituted PLV treated with cTn. cTnT (sTnT), cardiac (skeletal) troponin T; cTnI (sTnI), cardiac (skeletal) troponin I. sTn reconstitution ratio: sTnT, 107.0 ± 8.6%; sTnI, 117.7 ± 6.7% (*n* = 6) (residual cardiac subunits: ∼0% for both \[*n* = 6\]). cTn reconstitution ratio after sTn reconstitution: cTnT, 40.6 ± 4.4%; cTnI, 37.9 ± 2.9% (*n* = 5) (residual skeletal subunits: sTnT, 34.9 ± 6.0%; sTnI, 41.3 ± 11.5% \[*n* = 5\]). Tm, LC-1 and LC-2 denote tropomyosin, myosin light chain 1 and myosin light chain 2, respectively. (A, right) 2--7% gel. N2BA and N2B indicate large and small cardiac titins, respectively ([@bib14]; [@bib38]). T2, titin\'s degradation product(s). MHC, myosin heavy chain. (B) Typical chart recording showing force--pCa protocols. Arrows indicate percentage compared with the maximum obtained at the end of experiment (pCa 5.75). Gain, percent increase in Ca^2+^ sensitivity of force upon stretch (pCa 5.75). PF = 0, zero passive force (PF). (C, left) Force--pCa curves (top) and passive force (bottom) in control (*n* = 7) and sTn-reconstituted (*n* = 7) PLV at SL 1.9 and 2.3 μm. Black and red lines indicate control and sTn-reconstituted PLV, respectively. Inset, ΔpCa~50~ (C, control PLV). \*, P \< 0.05. (C, right) Force--pCa curves (top) and passive force (bottom) in rabbit psoas muscle (*n* = 7) and sTn-reconstituted PLV (same as in left) at SL 1.9 and 2.3 μm. Dashed black lines, rabbit psoas muscle. \*, P \< 0.05 compared with corresponding passive force in sTn-reconstituted PLV. Inset, ΔpCa~50~. (D) Comparison of SL-dependent increase in maximal force (ΔMaximal force). \*, P \< 0.05.](jgp1310275f01){#fig1}

Chart recordings of active force ([Fig. 1 B](#fig1){ref-type="fig"}) indicate that upon sTn reconstitution, maximal force decreased only slightly ([Table I](#tbl1){ref-type="table"}). At submaximal levels active force increased upon sTn reconstitution to an extent greater at SL 1.9 μm than at 2.3 μm, resulting in a decrease in the stretch-induced gain (i.e., from 52% to 21% at pCa 5.75).

###### 

Summary of the Values of Passive Force, Maximal Active Force, pCa~50~, ΔpCa~50~, and n~H~ in Control PLV, sTn-reconstituted PLV, and Control Rabbit Psoas Muscles

                                      SL     Passive force                                                                    Maximal force                                                                      pCa~50~                                                                          ΔpCa~50~                                       n~H~
  ----------------------------------- ------ -------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ---------------------------------------------- -------------
                                      *μ*m   mN/mm^2^                                                                         mN/mm^2^                                                                                                                                                                                                           
  [Fig. 1 C](#fig1){ref-type="fig"}                                                                                                                                                                                                                                                                                                              
      PLV                             1.9    ∼0                                                                               54.89 ± 2.24                                                                       5.56 ± 0.01                                                                                                                     3.83 ± 0.20
                                      2.3    10.11 ± 0.53                                                                     70.25 ± 3.87                                                                       5.81 ± 0.02                                                                      0.24 ± 0.01                                    3.11 ± 0.29
      PLV (+sTn)                      1.9    ∼0                                                                               51.43 ± 2.07 (54.36 ± 2.80)                                                        5.79 ± 0.01[a](#tblfn1){ref-type="table-fn"}                                                                                    3.20 ± 0.20
                                      2.3    10.23 ± 0.82                                                                     58.26 ± 3.58[a](#tblfn1){ref-type="table-fn"}                                      5.93 ± 0.02[a](#tblfn1){ref-type="table-fn"}                                     0.14 ± 0.02[a](#tblfn1){ref-type="table-fn"}   3.01 ± 0.10
      Rabbit psoas                    1.9    ∼0                                                                               161.72 ± 8.91[a](#tblfn1){ref-type="table-fn"} [b](#tblfn2){ref-type="table-fn"}   5.89 ± 0.03[a](#tblfn1){ref-type="table-fn"} [b](#tblfn2){ref-type="table-fn"}                                                  4.14 ± 0.22
                                      2.3    3.80 ± 0.76[a](#tblfn1){ref-type="table-fn"} [b](#tblfn2){ref-type="table-fn"}   178.68 ± 8.74[a](#tblfn1){ref-type="table-fn"} [b](#tblfn2){ref-type="table-fn"}   6.01 ± 0.02[a](#tblfn1){ref-type="table-fn"} [b](#tblfn2){ref-type="table-fn"}   0.12 ± 0.01[a](#tblfn1){ref-type="table-fn"}   3.40 ± 0.27
  Control experiments                                                                                                                                                                                                                                                                                                                            
      PLV (+cTn)                      1.9    ∼0                                                                               50.70 ± 3.15 (54.17 ± 4.50)                                                        5.60 ± 0.01                                                                                                                     3.28 ± 0.11
                                      2.3    7.90 ± 2.57                                                                      67.73 ± 3.70                                                                       5.82 ± 0.05                                                                      0.23 ± 0.04                                    2.60 ± 0.11
      Rabbit psoas (+sTn)             1.9    ∼0                                                                               129.40 ± 14.02 (129.35 ± 10.96)                                                    5.86 ± 0.03                                                                                                                     4.21 ± 0.31
                                      2.3    3.53 ± 0.52                                                                      152.58 ± 17.78                                                                     5.97 ± 0.04                                                                      0.11 ± 0.01                                    4.42 ± 0.55

Passive force was obtained at the steady state. PLV (+sTn), sTn-reconstituted PLV. Control experiments, muscles treated with the Tn complex identical to the endogenous one (see text). PLV (+cTn), cTn-reconstituted PLV (*n* = 5); Rabbit psoas (+sTn), sTn-reconstituted rabbit psoas muscle (*n* = 6). (P \> 0.05 compared with corresponding values for original muscles, except for n~H~ at SL 1.9 μm in PLV \[+cTn\]). Maximal force was obtained by activating muscle at pCa 4.5 prior to construction of the force--pCa curve at each SL (passive force was measured just prior to activation at pCa 4.5). Numbers in parentheses indicate maximal force values obtained prior to reconstitution (P \> 0.05 compared with corresponding values obtained after reconstitution).

P \< 0.05 compared with corresponding values for control PLV.

P \< 0.05 compared with corresponding values for sTn-reconstituted PLV.

Force--pCa curves revealed that sTn reconstitution increased Ca^2+^ sensitivity of force and diminished ΔpCa~50~ ([Fig. 1 C](#fig1){ref-type="fig"}, left). ΔpCa~50~ became similar to that obtained with rabbit fast skeletal (psoas) muscle ([Fig. 1 C](#fig1){ref-type="fig"}, right). Similarly, the SL-dependent increase in maximal Ca^2+^-activated force diminished upon sTn reconstitution and became similar to that obtained in rabbit psoas muscle ([Fig. 1 D](#fig1){ref-type="fig"}).

We confirmed that the treatment with the Tn complex identical to the endogenous one did not significantly change active and passive properties of cardiac and skeletal muscles at either SL ([Table I](#tbl1){ref-type="table"}; see also [Fig. 1 A](#fig1){ref-type="fig"} and [Fig. 2 A](#fig2){ref-type="fig"}), suggesting that our Tn exchange protocol creates reconstituted preparations that are interchangeable with the original muscles.

![cTn reconstitution and its impact on length-dependent activation in rabbit psoas muscle. (A, left) 15% gel. Cont., control fibers; cTn, cTn-reconstituted fibers; cTn-sTn, cTn-reconstituted fibers treated with sTn. cTn reconstitution ratio: cTnT, 59.2 ± 5.2%; cTnI, 52.7 ± 3.7% (*n* = 6) (residual skeletal subunits: sTnT, 54.6 ± 7.6%; sTnI, 56.2 ± 4.0% \[*n* = 6\]). sTn reconstitution ratio after cTn reconstitution: sTnT, 83.6 ± 5.4%; sTnI, 74.9 ± 9.2% (*n* = 6) (residual cardiac subunits: cTnT, 4.3 ± 2.9%; cTnI, 4.9 ± 2.7% \[*n* = 6\]). For abbreviations, see [Fig. 1](#fig1){ref-type="fig"}. (A, right) 2--7% gel. T1, intact fast skeletal titin. T2, titin\'s degradation product(s). (B) Typical chart recording showing force--pCa protocols. Arrows indicate percentage compared with the maximum obtained at the end of experiment (pCa 6.0). Gain, percent increase in Ca^2+^ sensitivity of force upon stretch (pCa 6.0). PF = 0, zero passive force (PF). (C), Force--pCa curves (top) and passive force (bottom) in control (*n* = 7) and cTn-reconstituted (*n* = 10) rabbit psoas muscle at SL 1.9 and 2.3 μm. Dashed black and solid blue lines indicate control and cTn-reconstituted fibers, respectively. Inset, ΔpCa~50~ (Psoas, control rabbit psoas muscle). \*, P \< 0.05. (D) Comparison of SL-dependent increase in maximal force (ΔMaximal force). \*, P \< 0.05.](jgp1310275f02){#fig2}

Effect of cTn Reconstitution on Length-dependent Activation in Skeletal Muscle
------------------------------------------------------------------------------

We then investigated whether reconstitution of skeletal thin filaments with cTn enhances length-dependent activation. A representative 15% gel shows that endogenous skeletal Tn subunits were decreased by ∼50% with a concomitant appearance of cardiac Tn subunits ([Fig. 2 A](#fig2){ref-type="fig"}). The incorporated cardiac Tn subunits were effectively replaced by skeletal isoforms upon subsequent sTn treatment (see legend of [Fig. 2 A](#fig2){ref-type="fig"} for quantitative analysis). Titin was unaffected by the reconstitution procedure ([Fig. 2 A](#fig2){ref-type="fig"}, right).

Chart recordings ([Fig. 2 B](#fig2){ref-type="fig"}) indicate that upon cTn reconstitution maximal force decreased slightly ([Table II](#tbl2){ref-type="table"}). Submaximal active force decreased upon cTn reconstitution to an extent greater at SL 1.9 μm than at 2.3 μm, and resulted in an increase in the stretch-induced gain (i.e., from 27% to 43% at pCa 6.0). Force--pCa curves revealed that Ca^2+^ sensitivity of force decreased and, importantly, ΔpCa~50~ increased ([Fig. 2 C](#fig2){ref-type="fig"}). ΔpCa~50~ was similar to that obtained in PLV (see [Fig. 1 C](#fig1){ref-type="fig"}). Similarly, the SL-dependent increase in maximal Ca^2+^-activated force increased upon cTn reconstitution, and became similar to that obtained in PLV ([Fig. 2 D](#fig2){ref-type="fig"}).

###### 

Summary of the Values of Passive Force, Maximal Active Force, pCa~50~, ΔpCa~50~, and n~H~ in cTn-reconstituted Rabbit Psoas Muscle

                                      SL     Passive force                                  Maximal force                                                                                      pCa~50~                                        ΔpCa~50~                                       n~H~
  ----------------------------------- ------ ---------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------------------- ---------------------------------------------- ----------------------------------------------
                                      *μ*m   mN/mm^2^                                       mN/mm^2^                                                                                                                                                                                         
  [Fig. 2 C](#fig2){ref-type="fig"}                                                                                                                                                                                                                                                          
      Rabbit psoas (+cTn)             1.9    ∼0                                             137.61 ± 8.67[b](#tblfn4){ref-type="table-fn"} (167.24 ± 13.15[b](#tblfn4){ref-type="table-fn"})   5.66 ± 0.04[a](#tblfn3){ref-type="table-fn"}                                                  2.97 ± 0.34[a](#tblfn3){ref-type="table-fn"}
                                      2.3    4.72 ± 0.82[b](#tblfn4){ref-type="table-fn"}   183.43 ± 10.81[b](#tblfn4){ref-type="table-fn"}                                                    5.89 ± 0.05[a](#tblfn3){ref-type="table-fn"}   0.24 ± 0.02[a](#tblfn3){ref-type="table-fn"}   2.23 ± 0.13^^a,b^^

Passive force was obtained at the steady state. Numbers in parentheses indicate maximal force values obtained prior to cTn reconstitution (P \< 0.05 compared with corresponding values obtained after cTn reconstitution). n~H~ decreased upon cTn reconstitution (see [Table I](#tbl1){ref-type="table"}), consistent with previous studies ([@bib31]; [@bib9]).

P \< 0.05 compared with corresponding values for control rabbit psoas muscle ([Table I](#tbl1){ref-type="table"}).

P \< 0.05 compared with corresponding values for control PLV ([Table I](#tbl1){ref-type="table"};).

Effect of sTn Reconstitution on Cross-Bridge Kinetics in Cardiac Muscle
-----------------------------------------------------------------------

The increase in Ca^2+^ sensitivity of force upon sTn reconstitution in cardiac muscle may result from the accelerated myosin binding to actin. Therefore, we tested the effect of sTn reconstitution on *k* ~tr~. At maximal activation, *k* ~tr~ did not significantly change upon sTn reconstitution (see legend of [Fig. 3](#fig3){ref-type="fig"}). However, it increased significantly at submaximal levels ([Fig. 3 A](#fig3){ref-type="fig"}), resulting in a leftward shift of the *k* ~tr~--pCa curve ([Fig. 3 B](#fig3){ref-type="fig"}, left). Under the control condition, force was more sensitive to Ca^2+^ than was *k* ~tr~ ([@bib27]), however, this relation was reversed upon sTn reconstitution ([Fig. 3 B](#fig3){ref-type="fig"}, right), indicating enhanced cross-bridge cycling at a given level of activation. Consistent with this view, the relationship of active force vs. *k* ~tr~ was shifted upward upon sTn reconstitution ([Fig. 3 C](#fig3){ref-type="fig"}).

![Effects of sTn reconstitution on force redevelopment in PLV. (A) Chart recording showing active force redevelopment in control (left) and sTn-reconstituted (right) PLV at similar activation levels. P~0~, maximal force. SL 1.9 μm. (B, left) *k* ~tr~--pCa (dashed lines) and force-pCa (solid lines) curves obtained from the same preparations (control, *n* = 8; sTn, *n* = 9). Maximal force was 46.97 ± 2.60 and 43.16 ± 2.38 (48.33 ± 3.51) mN/mm^2^ in control and sTn-reconstituted PLV (P \> 0.05), respectively (values in parentheses indicate maximal force before sTn reconstitution; P \> 0.05). n~H~ was 3.19 ± 0.22 and 3.38 ± 0.23 (P \> 0.05) in control and sTn-reconstituted PLV, respectively. Maximal *k* ~tr~ was 0.94 ± 0.07 and 0.89 ± 0.04 (0.89 ± 0.06) s^−1^ in control and sTn-reconstituted PLV (P \> 0.05), respectively (values in parentheses indicate *k* ~tr~ before sTn reconstitution; P \> 0.05). n~H~ was 1.78 ± 0.06 and 1.72 ± 0.12 (P \> 0.05) in control and sTn-reconstituted PLV, respectively. (B, right) Summary of the midpoints of the curves. \*, P \< 0.05, compared with the corresponding control values. ^\#^, P \< 0.05, compared with the corresponding force values. (C) Force--*k* ~tr~ relationship in control and sTn-reconstituted PLV. Statistical tests were done for points with insignificant X values. \*, P \< 0.05.](jgp1310275f03){#fig3}

Length-dependent Activation at High Passive Force in Cardiac Muscle
-------------------------------------------------------------------

To test whether length-dependent activation is enhanced at higher passive force, we manipulated the prehistory of stretch before activation at each pCa ([@bib14]). The force--pCa curve was shifted leftward with an increase in passive force in both control and sTn-reconstituted cardiac muscles ([Fig. 4 A](#fig4){ref-type="fig"}; see [Table III](#tbl3){ref-type="table"} for pCa~50~ values at SL 2.3 μm), resulting in a significant increase in ΔpCa~50~ in both muscles. The SL-dependent growth in maximal Ca^2+^-activated force also increased with passive force in both control (from 27.6 ± 2.2% to 42.8 ± 2.0%; P \< 0.05) and sTn-reconstituted (from 12.9 ± 3.4% to 22.0 ± 2.2%; P \< 0.05) muscles.

![Length-dependent activation at high passive force in PLV. (A) Force--pCa curves at SL 1.9 and 2.3 μm, with high passive force at 2.3 μm (dashed lines). Left, control PLV (*n* = 6); right, sTn-reconstituted PLV (*n* = 6). Data obtained at steady-state passive force are taken from [Fig. 1 C](#fig1){ref-type="fig"} and shown by solid lines. Inset, ΔpCa~50~ (High PF, high passive force). Bottom, passive force. \*, P \< 0.05 compared with the corresponding values obtained at steady-state passive force. (B), Relation between titin-based passive force and pCa~50~ (left) (slope: 0.020 and 0.016, in control and sTn-reconstituted PLV, respectively) or maximal Ca^2+^-activated force (right) (slope: 3.407 and 2.690, in control and sTn-reconstituted PLV, respectively). ΔTitin-based passive force denotes difference between the values of titin-based passive force at SL 1.9 and 2.3 μm.](jgp1310275f04){#fig4}

###### 

Summary of the Values of Passive Force, Maximal Active Force, pCa~50~, ΔpCa~50~, and n~H~ in Control and sTn-reconstituted PLV in High Passive Force Experiments

                                      SL              Passive force                                   Maximal force                                                                     pCa~50~                                                                          ΔpCa~50~                                       n~H~
  ----------------------------------- --------------- ----------------------------------------------- --------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ---------------------------------------------- -------------
                                      *μ*m            mN/mm^2^                                        mN/mm^2^                                                                                                                                                                                                          
  [Fig. 4 A](#fig4){ref-type="fig"}                                                                                                                                                                                                                                                                                     
      Control PLV                     1.9             ∼0                                              57.52 ± 1.92                                                                      5.56 ± 0.01                                                                                                                     4.33 ± 0.19
                                      2.3 (high PF)   14.50 ± 1.04[a](#tblfn5){ref-type="table-fn"}   82.23 ± 3.40[a](#tblfn5){ref-type="table-fn"}                                     5.89 ± 0.01[a](#tblfn5){ref-type="table-fn"}                                     0.33 ± 0.01[a](#tblfn5){ref-type="table-fn"}   3.77 ± 0.19
      PLV (+sTn)                      1.9             ∼0                                              56.33 ± 1.23 (59.21 ± 3.36)                                                       5.80 ± 0.03[b](#tblfn6){ref-type="table-fn"}                                                                                    3.76 ± 0.08
                                      2.3 (high PF)   15.45 ± 0.85[a](#tblfn5){ref-type="table-fn"}   68.53 ± 2.34[a](#tblfn5){ref-type="table-fn"} [b](#tblfn6){ref-type="table-fn"}   6.01 ± 0.02[a](#tblfn5){ref-type="table-fn"} [b](#tblfn6){ref-type="table-fn"}   0.21 ± 0.01[a](#tblfn5){ref-type="table-fn"}   3.84 ± 0.41

Passive force was obtained ∼10 s after increasing SL to 2.3 μm. Numbers in parentheses indicate maximal force values obtained prior to sTn reconstitution (P \> 0.05 compared with corresponding values obtained after sTn reconstitution).

P \< 0.05 compared with corresponding values obtained in experiments under steady-state passive force ([Table II](#tbl2){ref-type="table"}).

P \< 0.05 compared with corresponding values for control PLV at high passive force (high PF).

Both Ca^2+^ sensitivity of force and maximal Ca^2+^-activated force linearly depended on titin-based passive force in both control and sTn-reconstituted muscles ([Fig. 4 B](#fig4){ref-type="fig"}).

DISCUSSION
==========

In the present study, we demonstrated that quasi-complete reconstitution of cardiac thin filaments with sTn diminished length-dependent activation, to a similar level as that observed in skeletal muscle. sTn accelerated the cross-bridge formation, and length-dependent activation strongly correlated with titin-based passive force, irrespective of the Tn isoform. Furthermore, reconstitution of skeletal thin filaments with cTn enhanced length-dependent activation, accompanied by a decrease in Ca^2+^ sensitivity of force.

Several groups reported an inverse relationship between the cooperative thin filament activation and length-dependent activation. Using a strong-binding, non-force--generating analogue of myosin subfragment-1 (NEM-S1), [@bib16] first demonstrated that length-dependent activation is attenuated at high cooperative activation, consistent with our previous observation with MgADP ([@bib11]). Conversely, length-dependent activation is reportedly enhanced at low cooperative activation, regardless of the activator, i.e., either Ca^2+^ ([@bib12]) or rigor cross-bridges ([@bib34]). These findings are consistent with the notion that the magnitude of length-dependent activation depends on the fraction of recruitable cross-bridges.

sTn increased Ca^2+^ sensitivity of force ([Fig. 1](#fig1){ref-type="fig"}) and submaximal *k* ~tr~ ([Fig. 3](#fig3){ref-type="fig"}) in cardiac muscle. Upon sTn reconstitution, *k* ~tr~ became more sensitive to Ca^2+^ than force, and the active force--*k* ~tr~ relationship was shifted upward. These results indicate that sTn accelerates cross-bridge cycling in cardiac muscle. *k* ~tr~ is the sum of the apparent rate of cross-bridge attachment (*f* ~app~) and detachment (*g* ~app~) ([@bib5]). Therefore, it can increase due to an increase in either *f* ~app~ or *g* ~app~, or both. Considering, however, that sTn increased Ca^2+^ sensitivity of force, the increase in *k* ~tr~ is likely related to the relative increase in *f* ~app~, resulting in an increase in the fraction of strongly bound cross-bridges. We therefore conclude that sTn shifts the equilibrium of the thin filament state toward the "on" state and subsequently reduces the fraction of recruitable cross-bridges, resulting in blunted length-dependent activation, with a magnitude similar to that in skeletal muscle. This view is supported by the result of [Fig. 2](#fig2){ref-type="fig"} that cTn decreased Ca^2+^ sensitivity of force and enhanced length-dependent activation in skeletal muscle.

The reconstitution ratio was lower in rabbit psoas fibers with cTn (∼50% with 6 mg/ml; [Fig. 2 A](#fig2){ref-type="fig"}), as compared with that in PLV with sTn (∼100% with 2 mg/ml; [Fig. 1 A](#fig1){ref-type="fig"}). Moreover, ∼40% of the skeletal Tn subunits reconstituted in PLV were exchanged for cardiac isoforms upon cTn treatment ([Fig. 1 A](#fig1){ref-type="fig"}), whereas the cardiac Tn subunits reconstituted in rabbit psoas muscle were almost completely replaced by skeletal isoforms upon sTn treatment ([Fig. 2 A](#fig2){ref-type="fig"}). These results indicate that cTn has a lower binding affinity to both cardiac and skeletal thin filaments than sTn. By using rabbit psoas myofibrils, [@bib31] and [@bib9] achieved higher levels of reconstitution with cTn (∼100% in [@bib31], and ∼90% in [@bib9]), and reported that Ca^2+^ sensitivity of force increased, which, as the authors acknowledge, contradicts the intrinsic characteristics of cardiac vs. skeletal muscle. The effect of cTn reconstitution on Ca^2+^ sensitivity of force in skeletal muscle likely varies with the protocol. In the present study, we treated single fibers in Ca^2+^-free rigor solution containing BDM for a relatively short period (i.e., 1 h) to achieve partial reconstitution (∼50%), and, therefore, the abnormal on--off switching of the thin filament state that occurs possibly due to the damage upon reconstitution may have been avoided.

TnI directly modulates the thin filament state, in association with TnT and Tm ([@bib35]). Indeed, it has been reported that Ca^2+^ sensitivity of force is increased and length-dependent activation is blunted in hearts of transgenic mice expressing the slow skeletal TnI isoform ([@bib3]; [@bib24]). More recently, [@bib37] reported that a substitution of threonine for proline at position 144 in the inhibitory region of cTnI blunted length-dependent activation, via an unsolved mechanism. On the other hand, isoform switching of either TnC ([@bib29]; [@bib26]) or TnT ([@bib8]) reportedly does not alter length-dependent activation. Therefore, it is reasonable to conclude that the attenuation of length-dependent activation by sTn in PLV may primarily result from the replacement of TnI from cardiac to skeletal isoform.

Consistent with the previous reports ([@bib7]; [@bib13], [@bib14]), length-dependent activation was enhanced with an increase in passive force in both control and sTn-reconstituted muscles, and the length dependence linearly correlated with titin-based passive force ([Fig. 4](#fig4){ref-type="fig"}). Currently, the role of interfilament lattice spacing in length-dependent activation is under controversy; some groups have published papers that support the lattice spacing hypothesis (e.g., [@bib25]; [@bib10]; [@bib11]), but the de Tombe group has reported that Ca^2+^ sensitivity of force and the lattice spacing are not well correlated (e.g., [@bib22],[@bib23], [@bib24]). More recently, [@bib30] successfully showed in vivo that the lattice spacing plays a pivotal role in the regulation of ventricular pressure (see also [@bib36]). The aim of the present study was not to test the lattice spacing hypothesis; however, the result of [Fig. 4](#fig4){ref-type="fig"} is consistent with the notion that titin-based passive force promotes actomyosin interaction, such as by regulating the lattice spacing ([@bib7]; [@bib14]) and/or by straining the thick filament ([@bib13]), regardless of the thin filament state. Hence, we consider that titin-based passive force operates as a triggering factor in length-dependent activation.

It has been reported that length-dependent activation is attenuated in myocardium from the failing human heart ([@bib28]; [@bib33]). Therefore, the importance of the present study is further highlighted by the reports on Tn mutations (e.g., [@bib19]), as well as by those on changes in titin isoform expression (e.g., [@bib17]), in heart failure, since our findings indicate that the attenuation of length-dependent activation in failing myocardium may be due, at least in part, to the changes in Tn and/or titin. Future studies should be directed to elucidating the relations between length-dependent activation and sarcomere protein expression changes in various modes of heart failure.

In conclusion, Tn and titin regulate the Frank-Starling mechanism of the heart in a coordinated fashion, such that the fraction of cross-bridges formed via titin-based passive force varies in a Tn isoform-dependent manner.
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